ImmunityBio (IBRX) Accumulated Expenses (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Accumulated Expenses of $48.2 million for Q1 2026, up 72.84% year-over-year from $27.9 million in Q1 2025, and up 2.92% quarter-over-quarter from $46.8 million in Q4 2025.
ImmunityBio (IBRX) Accumulated Expenses (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Accumulated Expenses for 13 consecutive years, with $48.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 72.84% year-over-year to $48.2 million; the TTM figure through Mar 2026 stood at $48.2 million (up 72.84% YoY), while the FY2025 annual figure was $46.8 million, up 15.42% from the prior year.
- Accumulated Expenses rose to $48.2 million in Q1 2026 per IBRX's latest filing, from $46.8 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $64.9 million in Q3 2023 and bottomed at $44000.0 in Q2 2024.
- Historically, Accumulated Expenses has averaged $41.4 million across 5 years, with a median of $43.6 million in 2025.
- Annual changes were most pronounced in 2024 — Accumulated Expenses sank 99.93% — and 2025, when it jumped 81047.73%.
- ImmunityBio's Accumulated Expenses stood at $41.8 million in 2022, then rose by 2.11% to $42.7 million in 2023, then decreased by 4.98% to $40.6 million in 2024, then increased by 15.42% to $46.8 million in 2025, then grew by 2.92% to $48.2 million in 2026.
- Business Quant data shows IBRX's Accumulated Expenses at $48.2 million in Q1 2026, $46.8 million in Q4 2025, and $43.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.67 Mn |
| Mar 31, 2026 | 48.20 Mn |
| Dec 31, 2025 | 46.84 Mn |
| Sep 30, 2025 | 43.60 Mn |
| Jun 30, 2025 | 35.71 Mn |
| Mar 31, 2025 | 27.89 Mn |
| Dec 31, 2024 | 40.58 Mn |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Mar 31, 2024 | 32.71 Mn |
| Dec 31, 2023 | 42.71 Mn |
| Sep 30, 2023 | 64.87 Mn |
| Jun 30, 2023 | 62.34 Mn |
| Mar 31, 2023 | 54.12 Mn |
| Dec 31, 2022 | 41.83 Mn |
| Sep 30, 2022 | 46.22 Mn |
| Jun 30, 2022 | 52.35 Mn |
| Mar 31, 2022 | 62.47 Mn |
| Dec 31, 2021 | 51.39 Mn |
| Sep 30, 2021 | 38.52 Mn |